Skip to main content
Clinical Kidney Journal logoLink to Clinical Kidney Journal
. 2021 Jul 14;14(9):2136. doi: 10.1093/ckj/sfab104

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial

Christoph Wanner, Mark E Cooper, Odd Erik Johansen, Robert Toto, Julio Rosenstock, Darren K McGuire, Steven E Kahn, Egon Pfarr, Sven Schnaidt, Maximilian von Eynatten, Jyothis T George, Nicholas D Gollop, Nikolaus Marx, John H Alexander, Bernard Zinman, Vlado Perkovic, on behalf of the CARMELINA investigators
PMCID: PMC8406051  PMID: 34476096

Clinical Kidney Journal, sfaa225, https://doi.org/10.1093/ckj/sfaa225

In the originally published version of this manuscript, the legend for Figure 4 incorrectly directed the reader to the right side of the curve, this has been corrected to read: ‘Point estimates on the left side of the curve indicate a positive effect for LINA.’


Articles from Clinical Kidney Journal are provided here courtesy of Oxford University Press

RESOURCES